Generate Biomedicines (NASDAQ:GENB) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Generate Biomedicines Inc (NASDAQ:GENB) shares crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $14.14 and traded as low as $12.46. Generate Biomedicines shares last traded at $12.57, with a volume of 1,298,162 shares trading hands.

Wall Street Analyst Weigh In

GENB has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. HC Wainwright restated a “buy” rating on shares of Generate Biomedicines in a report on Friday, October 30th. Finally, Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.40.

Generate Biomedicines Stock Down 11.2%

The stock has a market cap of $1.61 billion and a price-to-earnings ratio of -7.91. The stock has a fifty day moving average of $14.67 and a two-hundred day moving average of $14.14.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. Equities research analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Trading of Generate Biomedicines

A number of institutional investors have recently modified their holdings of GENB. Susquehanna International Group LLP purchased a new position in Generate Biomedicines in the second quarter valued at approximately $196,000. AXQ Capital LP acquired a new position in Generate Biomedicines during the second quarter valued at approximately $218,000. Summa Corp. purchased a new stake in Generate Biomedicines during the third quarter worth approximately $250,000. Magnus Financial Group LLC grew its stake in Generate Biomedicines by 39.4% during the third quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock worth $327,000 after buying an additional 6,150 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Generate Biomedicines in the second quarter worth $530,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company’s research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.